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Proton pump inhibitors (PPIs) are widely used drugs that may increase the cardiovascular risk by me-
chanisms not entirely known. While PPIs increase asymmetric dimethylarginine (ADMA) levels and in-
hibit nitric oxide production, it is unknown whether impaired vascular redox biology resulting of in-
creased xanthine oxidoreductase (XOR) activity mediates PPIs-induced endothelial dysfunction (ED). We
examined whether increased XOR activity impairs vascular redox biology and causes ED in rats treated
with omeprazole. We also examined whether omeprazole aggravates the ED found in hypertension.
Treatment with omeprazole reduced endothelium-dependent aortic responses to acetylcholine without
causing hypertension. However, omeprazole did not aggravate two-kidney, one-clip (2K1C) hyperten-
sion, nor hypertension-induced ED. Omeprazole and 2K1C increased vascular oxidative stress as assessed
with dihydroethidium (DHE), which reacts with superoxide, and by the lucigenin chemiluminescence
assay. The selective XOR inhibitor febuxostat blunted both effects induced by omeprazole. Treatment
with omeprazole increased plasma ADMA concentrations, XOR activity and systemic markers of oxidative
stress. Incubation of aortic rings with ADMA increased XOR activity, DHE fluorescence and lucigenin
chemiluminescence signals, and febuxostat blunted these effects. Providing functional evidence that
omeprazole causes ED by XOR-mediated mechanisms, we found that febuxostat blunted the ED caused
by omeprazole treatment. This study shows that treatment with omeprazole impairs the vascular redox
biology by XOR-mediated mechanisms leading to ED. While omeprazole did not further impair hy-
pertension-induced ED, further studies in less severe animal models are warranted. Our findings may
have major relevance, particularly to patients with cardiovascular diseases taking PPIs.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Proton pump inhibitors (PPIs) are over-the-counter drugs
widely used in gastroenterology because they inhibit gastric acid
secretion. While PPIs have usually been considered relatively safe
drugs, recent studies suggest that the use of omeprazole increases
the risk of acute myocardial infarction [1–3]. At least two me-
chanisms involving impaired nitric oxide (NO) activity have been
implicated in the increased cardiovascular risk associated with the
use of PPIs. First, these drugs were shown to elevate the con-
centrations of a NO synthase (NOS) inhibitor, asymmetric di-
methylarginine (ADMA) [4], which inhibits NOS. Second, inter-
ference with gastric formation of protective NO-related speciesB.V. This is an open access article ufrom dietary nitrite and nitrate may also impair non-enzymatic
formation of NO and normal cardiovascular function [5–8].
Although these mechanisms disturbing NO biology may impair
vascular redox biology and cause endothelial dysfunction [9], no
previous study has examined the possibility that omeprazole
causes endothelial dysfunction by activating other critical me-
chanisms leading to endothelial dysfunction. Indeed, while ome-
prazole and other PPIs increase ADMA concentrations [4], no
previous study has examined the possibility that PPIs may impair
vascular redox biology by mechanisms increasing the formation of
reactive oxygen species (ROS), thus promoting endothelial dys-
function. Examining this possibility is important because PPIs used
to be accepted as a safe therapy without major adverse effects on
the cardiovascular system. However, mounting clinical evidence
now challenges this view [1–3]. Astonishingly, some studies sug-
gest that omeprazole exerts antioxidant effects [10] and may in-
duce vascular relaxation that is partially NO-mediated [11,12], andnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ovascular system. However, these previous studies have not as-
sessed in vivo effects of omeprazole on the vascular function, and it
is possible that increased ADMA concentrations after treatment
with omeprazole [4] decrease NO activity and promote prooxidant
mechanisms and vascular dysfunction.
Because NO down-regulates xanthine oxidoreductase (XOR)
activity [13], a major contributor to oxidative stress in many car-
diovascular diseases [13,14], we hypothesized that omeprazole
increases ADMA concentrations, which impair NO formation and
cause endothelial dysfunction by increasing XOR activity and im-
pairing vascular redox biology. While previous studies showed
that ADMA promotes tissue oxidative stress [15], a direct re-
lationship between PPIs-induced increases in ADMA concentra-
tions and vascular oxidative stress has not been shown. This me-
chanism possibly activated by PPIs may be critically involved in
the vascular dysfunction and enhanced cardiovascular risk of pa-
tients taking PPIs. In addition, given that omeprazole is widely
prescribed to hypertensive subjects, we examined whether treat-
ment with omeprazole further impairs hypertension-induced
vascular dysfunction.2. Materials and methods
2.1. Animals, treatment with omeprazole and hypertension model
This study followed the guidelines of the Ribeirao Preto Med-
ical School, University of Sao Paulo, and the animals were handled
according to the guiding principles published in the National In-
stitutes of Health Guide for the Care and Use of Laboratory Ani-
mals. Male Wistar rats (180–200 g) from the colony at University
of São Paulo were maintained at room temperature (22–25 °C) on
light/dark cycle (12 h) and had free access to standard rat chow
and water.
To assess the cardiovascular effects of omeprazole, the rats
were treated with omeprazole 10 mg/kg i.p. (or vehicle) daily [5,6]
for four weeks. This dose significantly impaired antihypertensive
effects associated with increased nitric oxide formation [5–7] .
Moreover, to examine the possibility that treatment with ome-
prazole further impairs the cardiovascular alterations of hy-
pertension, the same treatment with omeprazole (or vehicle) was
administered to two kidney, one clip (2K1C)-hypertensive rats.
Treatment with omeprazole started after two weeks of hyperten-
sion, when the animals were randomly allocated to treatment with
omeprazole or control group.
2K1C hypertension was induced as previously described
[16,17]. Systolic blood pressure (SBP) was assessed weekly by tail-
cuff plethysmography [18]. By the end of the sixth week of study,
the rats were anesthetized with tribromoethanol (250 mg/kg), and
arterial blood samples were collected into tubes containing he-
parin for further biochemical determinations. The thoracic aorta
was carefully excised, cleaned of adherent connective tissues and
fat, and cut into 4 mm rings for biochemical determinations and
vascular reactivity assessment. One ring was embedded in tissue-
teks and used later to prepare cryosections.
2.2. Assessment of changes in vascular reactivity associated with
omeprazole treatment and/or hypertension
To assess the effects of omeprazole treatment and/or hy-
pertension on vascular function, the thoracic aorta was carefully
excised as described above, and cut into 4 mm rings. The rings
were studied as previously detailed [19]. Endothelial integrity was
examined by assessing the relaxation in response to acetylcholine
(106 mol/L) under contractile tone induced by phenylephrine(107 mol/L). Thereafter, the aortic rings with intact, functional
endotheliumwere precontracted with phenylephrine (107 mol/L)
and the relaxing responses to cumulative concentrations (from
1010 to 105 mol/L) of acetylcholine were measured to construct
concentration-response curves. These experiments were carried
out using aortas from normotensive (or 2K1C hypertensive) rats
treated with omeprazole (or vehicle).
2.3. Assessment of gastric washing pH
The effects of omeprazole on gastric pH were assessed by
measuring gastric washing pH as previously detailed [6].
2.4. Assessment of vascular reactive oxygen species production
To assess vascular oxidative stress, two independent bio-
chemical assays were used to assess reactive oxygen species (ROS)
production. First, superoxide production by the aortas was mea-
sured by dihydroethidium (DHE), as previously described [20].
Aortic cryosections (5 mm thick) were incubated with DHE
(10 mmol/l) for 30 min and examined by fluorescence microscopy
(Leica Imaging Systems Ltd., Cambridge, England) at 400 using
λ¼525 nm excitation and λ¼605 nm emission, which is not
specific to detect only superoxide [21].
In some experiments, the aortas were pretreated for 1 h with
Tiron (1 mmol/L, a superoxide scavenger) [22], diphenyl iodonium
(DPI 10 mmol/L, a flavoprotein inhibitor) [22], tempol (100 mmol/L,
a superoxide dismutase analogue) [23], oxypurinol (300 mmol/L, a
XOR inhibitor) [24], febuxostat (50 nmol/L, a selective XOR in-
hibitor) [25] or asymmetric dimethylarginine (ADMA, 1 mmol/L).
Second, to further explore the effects of omeprazole and/or
hypertension on vascular ROS production, NADPH-dependent su-
peroxide production by aortic tissue was measured as previously
described [26]. Some experiments were performed in the absence
or presence of febuxostat (50 nmol/L) or DPI (10 mmol/L).
2.5. Assessment of vascular and plasma xanthine oxidase activity
Aortic and plasma xanthine oxidoreductase activity were
measured as previously described [27], with a commercial
fluorometric assay kit (Cayman Chemical Co., Ann Arbor, MI, USA,
item number 10010895), following the manufacturer’s instruc-
tions. Some experiments were performed in presence of febuxo-
stat (50 nmol/L), a selective inhibitor or xanthine oxide reductase
[25].
2.6. Assessment of circulating markers of oxidative stress (plasma
lipid peroxide and 8-isoprostanes)
To examine whether treatment with omeprazole affects the
circulating levels of markers of oxidative stress, plasma lipid per-
oxide (determined by measuring thiobarbituric acid reactive sub-
stances; TBARS) and 8-isoprostanes concentrations were de-
termined. TBARS were measured by a fluorometric method, as
previously detailed [28].
2.7. Assessment of plasma asymmetric dimethylarginine (ADMA)
concentrations
Because treatment with omeprazole or other PPIs increases the
formation of ADMA, the plasma ADMA concentrations were
measured both in normotensive and hypertensive rats treated
with omeprazole (or vehicle) with a commercially available en-
zyme-linked immunosorbent assay kit (MyBioSource, San Diego,
CA, USA, item number: MBS703256).
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ROS and the possible role of XOR in ADMA-induced oxidative stress
Given the fact that treatment with omeprazole increased cir-
culating ADMA concentrations in association with increased vas-
cular production of ROS, experiments were carried out with aortic
rings incubated for three hours with ADMA (1 mM) or vehicle. This
concentration is similar to the plasma concentration found after
treatment with omeprazole and to those previously used [29]. The
incubation conditions were the same as those used in aortic ring
reactivity experiments described above. Therefore, to assess the
possible role of XOR and other flavoproteins in increasing vascular
ROS production by ADMA, incubations with ADMA were carried
out in the presence of febuxostat (50 nmol/L) [25] or DPI (10 mmol/
L) [22]. After incubation, reactive oxygen species (ROS) production
in the aortas were measured by dihydroethidium (DHE) as de-
scribed above. To further confirm the results obtained with DHE,
NADPH-dependent superoxide production by aortic tissue was
measured as described above.
To further confirm that XOR activity increases after incubation
with ADMA, XOR activity was assessed in aortic rings incubated
with ADMA (1 mM) or vehicle, and the effects of febuxostat
(50 nmol/L) [25] were also examined.
2.9. Assessment of the role of XOR in the changes in vascular re-
activity associated with omeprazole treatment
Given that treatment with omeprazole significantly impaired
the endothelial function and increased vascular XOR activity and
oxidative stress, experiments designed to assess the role of XOR in
the changes in vascular reactivity were carried out using the same
methodology as described above. Endothelium-dependent re-
sponses were studied in aortic rings from animals treated with
omeprazole (or vehicle) in the presence or absence of the XOR
inhibitor febuxostat (107 mol/L) or vehicle (dimethyl sulfoxide;
DMSO 0.0004%).
2.10. Drugs and solutions
All drugs and reagents were purchased from Sigma Chemical
Co. (St Louis, MO, USA) and all solutions were prepared im-
mediately before use.
2.11. Statistical analysis
The results are expressed as means7S.E.M. The comparisons
between groups were assessed by one-way or two-way analysis of
variance followed by the Tukey test. A probability value Po0.05
was considered significant.3. Results
3.1. Treatment with omeprazole causes endothelial dysfunction
without significantly increasing arterial blood pressure
We found that chronic treatment with omeprazole neither in-
creased SBP nor significantly aggravated 2K1C hypertension
(Fig. 1a), even though SBP tended to show slightly higher values in
2K1C hypertensive rats treated with omeprazole as compared with
hypertensive rats treated with vehicle (19677 versus
18377 mmHg, respectively; not significant).
While no major effects of omeprazole on blood pressure were
found, chronic treatment with this PPI shifted the concentration-
effect curve in response to acetylcholine to the right
(pD2¼7.270.1 and pD2¼6.770.1, respectively, in controls and inomeprazole-treated animals; Po0.05; Fig. 1c and d). Moreover,
treatment with omeprazole decreased the maximum responses to
acetylcholine (Emax¼9272% and Emax¼7973%, respectively, in
controls and in omeprazole-treated animals; Po0.05; Fig. 1c and
e). However, whereas chronic treatment with omeprazole im-
paired the endothelial-dependent responses to acetylcholine to
the same degree as 2K1C hypertension, treatment of 2K1C hy-
pertensive rats with the same dose of omeprazole did not further
impair the responses to acetylcholine (P40.05; Fig. 1c, d, and e).
Therefore, omeprazole caused endothelial dysfunction similar to
that found in 2K1C hypertension, without aggravating it.
Fig. 1b shows that treatment with omeprazole increased gastric
washing pH, both in normotensive and in 2K1C hypertensive rats
(both Po0.05; Fig. 1b).
3.2. Treatment with omeprazole increases vascular oxidative stress,
which is mostly attributable to increased xanthine oxidase (XOR)
activity
Increased oxidative stress is an important mechanism pro-
moting endothelial dysfunction, and therefore we assessed vas-
cular oxidative stress using two approaches. First, the vascular
production of ROS was examined in aortas from rats treated with
omeprazole by using the fluorescent superoxide indicator DHE
(Fig. 2a). Interestingly, we found a 44-fold increase in vascular
ROS levels in normotensive rats treated with omeprazole as
compared with vehicle (Po0.05; Fig. 2b). While 2K1C hyperten-
sion increased vascular ROS levels by 45-fold (Po0.05; Fig. 2b),
treatment with omeprazole did not further increase this para-
meter. Quantification of DHE fluorescence in control experiments
using aortas from hypertensive rats showed that the superoxide
scavenger tiron, or the flavoprotein inhibitor DPI, or the super-
oxide dismutase analogue tempol, or the XOR inhibitor oxypurinol
blunted DHE signal by 480% (Fig. 2c), thus suggesting that this
signal is attributable to the activity of flavoproteins including
NADPH oxidase and XOR.
Second, to confirm that omeprazole increases vascular oxida-
tive stress, we measured NADPH-dependent superoxide produc-
tion by aortas from rats using the lucigenin chemiluminescence
assay. In agreement with the DHE results, we found that treatment
of normotensive rats with omeprazole increased vascular NADPH-
dependent superoxide production by approximately 100%,
whereas hypertension increased this parameter by approximately
200% (both Po0.05; Fig. 3a). Treatment of hypertensive rats with
omeprazole was associated with lucigenin chemiluminescence
similar to that found after treatment of normotensive rats with
omeprazole (Fig. 3a). Control experiments with inhibitors of en-
zymes involved in superoxide production showed that the flavo-
protein inhibitor DPI inhibited 70–80% of lucigenin chemilumi-
nescence signal in aortic rings from normotensive rats treated
with vehicle or with omeprazole (both Po0.05; Fig. 3b). These
results suggest that 70–80% of NADPH-dependent superoxide
production by aortas is due to the activity of flavoproteins.
Importantly, 455% of the lucigenin chemiluminescence signal
was blunted when aortic rings from normotensive rats treated
with omeprazole were incubated with the selective XOR inhibitor
febuxostat (Po0.05; Fig. 3b), thus suggesting that XOR activity is
the major player in this signal.
To confirm that treatment with omeprazole increases vascular
XOR activity, we used a fluorometric assay to measure XOR activity
in aortic rings from normotensive and in 2K1C hypertensive rats
treated with omeprazole (or vehicle). Treatment of normotensive
rats with omeprazole increased vascular XOR activity to the same
degree as 2K1C hypertension (by approximately4120%; Fig. 3c;
both Po0.05). Slightly higher vascular XOR activity was found in
hypertensive rats treated with omeprazole (Fig. 3c; not
Fig. 1. Chronic treatment with the proton pump inhibitor omeprazole causes endothelial dysfunction without significantly increasing arterial blood pressure. (a) Systolic
blood pressure in normotensive and in 2K1C hypertensive rats treated with omeprazole (or vehicle). The arrow indicates the start of omeprazole or vehicle treatment.
(b) Gastric wash pH measured at the end of the study period. (c) Endothelial cell-dependent vasorelaxation induced by acetylcholine (Ach) in aortic rings from normotensive
and from 2K1C hypertensive rats treated with omeprazole (or vehicle). (d) pD2 values ( log of the molar concentration of Ach that produces 50% of the maximal effect).
(e) Maximal responses to Ach. Data are shown as mean7S.E.M. (n¼8–10/group in Fig. 1a and b; n¼5/group in Fig. 1c, d, and e). * Po0.05 versus normotensive animals
treated with vehicle.
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febuxostat showed that this inhibitor blunted 485% of vascular
XOR activity measured in aortic rings from rats treated with
omeprazole (Po0.05; Fig. 3d).
3.3. Treatment with omeprazole increases the plasma XOR activity
and the concentrations of systemic markers of oxidative stress
To further validate our results showing increased vascular
oxidative stress and XOR activity after treatment with omeprazole,
relevant systemic markers oxidative stress were assessed in plas-
ma samples, including plasma XOR activity. As expected, hy-
pertension increased plasma XOR activity and lipid peroxide
concentrations measured as MDA concentrations by approxi-
mately 15%, and treatment of normotensive rats with omeprazole
increased both parameters to the same degree as hypertension (all
Po0.05; Fig. 4a and b). However, treatment of hypertensive rats
with omeprazole did not further increase plasma XOR activity and
MDA concentrations (both P40.05; Fig. 4a and b). While treat-
ment with omeprazole did not increase plasma 8-isoprostanes
concentrations in normotensive rats, higher concentrations of this
marker were found in hypertensive rats treated with vehicle or
with omeprazole, as compared with their normotensive controls
(both Po0.05; Fig. 4c). Together, these results suggest thattreatment with omeprazole apparently increases systemic oxida-
tive stress.
3.4. Treatment with omeprazole increases the circulating con-
centrations of asymmetric dimethylarginine (ADMA), and ADMA in-
creases vascular oxidative stress via XOR activation
Previous studies with PPIs showed that they increase the
concentrations of ADMA [4], and therefore plasma ADMA con-
centrations were measured in the present study. As shown in
Fig. 5a, treatment with omeprazole increased ADMA concentra-
tions by approximately 90% and 330% in normotensive and in
hypertensive rats, respectively (both Po0.05; Fig. 5a).
To examine a possible link between the increases in circulating
ADMA concentrations and enhanced vascular XOR activity and
oxidative stress associated with omeprazole treatment, aortic
rings from normotensive rats were incubated ADMA and vascular
ROS levels were determined as described above (DHE and luci-
genin assays). Interestingly, the incubation with ADMA (1 mM)
increased vascular ROS concentrations by 4200%, and this effect
was completely blunted by the co-incubation with the selective
XOR inhibitor febuxostat (50 nmol/L) (both Po0.05; Fig. 5b; re-
presentative DHE-aortic cryosections in Fig. 5c). In agreement with
DHE results, NADPH-dependent superoxide production by aortic
Fig. 2. Chronic treatment with the proton pump inhibitor omeprazole increases the vascular formation of reactive oxygen species (ROS). (a) Representative photo-
micrographs (400) with red fluorescence of dihydroethidium (DHE)-aortic cryosections. (b) Quantification of aortic DHE fluorescence in each experimental group.
(c) Quantification of aortic DHE fluorescence in positive control experiments using aortas from hypertensive rats. Tiron (1 mmol/L, a superoxide scavenger), DPI (10 mmol/L, a
flavoprotein inhibitor), tempol (100 mmol/L, a superoxide dismutase analogue), and oxypurinol (300 mmol/L, a XOR inhibitor) blunted DHE signal by 480%. Data are shown
as mean7S.E.M. (n¼4–8/group). *Po0.05 versus normotensive animals treated with vehicle. #Po0.05 versus Vehicle.
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effect was totally inhibited by co-incubation with febuxostat or
with DPI, which is a non selective inhibitor of flavoproteins (all
Po0.05; Fig. 5d).
To further confirm the involvement of increased XOR activity
after incubation with ADMA, XOR activity was assessed in aortic
rings incubated with ADMA. In agreement with the other results,
ADMA (1 mM) increased aortic XOR activity by approximately
100%, and febuxostat (50 nmol/L) completely blunted this effect
(both Po0.05; Fig. 5e).
3.5. The selective XOR inhibitor febuxostat blunts the endothelial
dysfunction caused by chronic treatment with omeprazole, both in
normotensive and in hypertensive rats
The initial experiments showed that treatment with omepra-
zole impaired the endothelial function in association with in-
creased vascular XOR activity and oxidative stress. Therefore, the
effects of selective XOR inhibition on vascular function were ex-
amined. Incubation with febuxostat improved endothelium-de-
pendent responses of aortic rings from animals treated with
omeprazole, but not in control rats treated with vehicle, as re-
vealed by the increases in both pD2 values and in the maximal
responses to Ach (both Po0.05; Fig. 6a). Very similar effects were
found in hypertensive rats treated with omeprazole (or vehicle;
Fig. 6b). These results indicate that XOR inhibition with febuxostat
blunts the impairment in endothelial-dependent vascular re-
sponses caused by treatment with omeprazole.
4. Discussion
This study showed that treatment with omeprazole causesendothelial dysfunction by mechanisms that involve increased
ADMA levels [4] and impaired NO activity. Our results show for the
first time that omeprazole impairs vascular redox biology as a
result of increased formation of ROS, and this effect is associated
with enhanced vascular XOR activity, probably caused by increased
ADMA levels. While hypertension does not aggravate the effects of
omeprazole, a selective XOR inhibitor prevents the biochemical
and functional alterations associated with this PPI.
The wide use of PPIs is now of great concern because growing
evidence suggests that they may significantly increase the cardi-
ovascular risk [1–3,30] by mechanisms that are independent of
their pharmacokinetic interactions with clopidogrel, which could
impair the bioactivation of this antiplatelet agent and increase the
risk of clinically relevant events [31]. However, there is little in-
formation regarding the mechanisms that may explain how PPIs
have deleterious effects on the cardiovascular system [30]. As re-
cently shown, PPIs may inhibit the activity of the enzyme that
metabolizes ADMA, and therefore enhance ADMA concentrations
reducing NOS activity and endogenous NO production [4,30]. Our
results showing increased ADMA levels after treatment with
omeprazole support this mechanism. However, omeprazole may
also prevent the gastric formation of protective NO-related species
from dietary nitrite and nitrate [5–8] and further deteriorate NO
biology. Interestingly, while the effects of omeprazole on NO
biology are probably not so severe that hypertension ensues, this
PPI clearly induces endothelial dysfunction, as revealed by im-
paired responses to acetylcholine reported here and in previous
studies [4].
Our results strongly suggest that omeprazole may cause en-
dothelial dysfunction by impairing vascular redox biology. To
provide evidence that omeprazole induces vascular oxidative
Fig. 3. Chronic treatment with the proton pump inhibitor omeprazole increases NADPH-dependent superoxide production by vascular tissue, and this effect involves
increased vascular XOR activity. (a) NADPH-dependent superoxide production measured as lucigenin chemiluminescence in the aortic rings from normotensive and in 2K1C
hypertensive rats treated with omeprazole (or vehicle) (n¼7/group). (b) NADPH-dependent superoxide production by aortic rings from normotensive rats chronically
treated with vehicle (open bars) or omeprazole (hatched bars) and incubated with vehicle or DPI (10 mmol/L, a flavoprotein inhibitor), or with febuxostat (50 nmol/L, a
selective XOR inhibitor)(n¼3–7/group). (c) Xanthine oxidoreductase (XOR) activity measured by a fluorometric assay in the aortic rings from normotensive and in 2K1C
hypertensive rats treated with omeprazole (or vehicle)(n¼5–7/group). (d) XOR activity measured by a fluorometric assay in the aortic rings from normotensive rats
chronically treated with vehicle (open bar) or omeprazole (hatched bars) and incubated (or not) with the selective XOR inhibitor febuxostat (50 nmol/L)(n¼5/group). Data
are shown as mean7S.E.M. *Po0.05 versus normotensive animals treated with vehicle. #Po0.05 versus normotensive animals treated with Omeprazole.
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systemic redox state. We found that treatment with omeprazole
caused major increases in systemic and vascular ROS levels,
probably as a result of increased vascular XOR activity because
treatment with the selective XOR inhibitor completely blunted the
vascular increases in ROS and the endothelial dysfunction asso-
ciated with omeprazole. Because treatment with omeprazole in-
creases ADMA concentrations [4], we hypothesized that ADMA
would be critically involved in the activation of vascular XOR, thus
leading to increased ROS formation. Our results showing that
ADMA increases vascular XOR activity and ROS formation are
consistent with this mechanism and agree with previous studiesshowing that ADMA induces oxidative stress [15,32].
To support the idea that XOR plays a critical role in ADMA-in-
duced oxidative stress, we used the selective XOR inhibitor fe-
buxostat, which completely blunted the increases in both DHE
signal and the lucigenin chemiluminescence induced by ADMA in
vascular tissue. Even though a prooxidant mechanism involving
ADMA-induced NOS inhibition has been previously suggested [15],
febuxostat is not known to affect NOS activity, and therefore its
inhibitory effects on both vascular oxidative stress and on en-
dothelial dysfunction are not attributable to interference with NOS
activity. Conversely, febuxostat, a XOR-specific inhibitor [25],
blunted omeprazole-induced oxidative stress in vivo, thus critically
Fig. 4. Treatment with omeprazole increases the circulating concentrations of markers of oxidative stress. (a) Xanthine oxidoreductase (XOR) activity measured by a
fluorometric assay (n¼8–10/group). (b) Plasma lipid peroxide concentrations measured with a fluorometric assay and expressed as malondialdehyde (MDA) concentrations
(n¼7/group). (c) Plasma 8-isoprostanes (8-isoPGF2α) concentrations measured with a enzyme-linked immunosorbent assay (n¼7/group). Data are shown as mean7S.E.M.
*Po0.05 versus normotensive animals treated with vehicle.
Fig. 5. Treatment with omeprazole increases the circulating concentrations of asymmetric dimethylarginine (ADMA), which increases vascular oxidative stress by me-
chanisms involving xanthine oxidoreductase (XOR) activation. (a) ADMA concentrations measured with enzyme-linked immunosorbent assay in plasma samples from
normotensive and 2K1C hypertensive rats treated with omeprazole (or vehicle) (n¼4–7/group). (b) Quantification of dihydroethidium (DHE) fluorescence in aortic rings
from normotensive rats, incubated for three hours with ADMA (1 mM) or vehicle, and with ADMA (1 mM) in the presence of the selective XOR inhibitor febuxostat (50 nmol/L)
(n¼6–8/group). (c) Representative photomicrographs (400) with red fluorescence of DHE-aortic cryosections after incubation of aortic rings with ADMA (1 mM) or vehicle
(Control), and ADMA (1 mM) in the presence of febuxostat. (d) NADPH-dependent superoxide production measured as lucigenin chemiluminescence in the aortic rings from
normotensive rats, incubated for three hours with ADMA (1 mM), or vehicle, or with the flavoprotein inhibitor DPI (10 mmol/L), or with ADMA (1 mM) in the presence of
febuxostat (50 nmol/L)(n¼3–10/group). (e) XOR activity measured by a fluorometric assay in the aortic rings from normotensive rats, incubated for three hours with ADMA
(1 mM) or vehicle, and with ADMA (1 mM) in the presence of febuxostat (50 nmol/L)(n¼3–8/group). Data are shown as mean7S.E.M. *Po0.05 versus normotensive animals
treated with vehicle (panel a). *Po0.05 versus Vehicle (panels b, d, e). #Po0.05 versus ADMA (panels b, d, e).
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omeprazole. To further confirm this new mechanism linking in-
creased ADMA concentrations and enhanced vascular XORactivity/oxidative stress, we incubated aortic rings with ADMA.
Interestingly, we found that ADMA increased vascular ROS levels
and superoxide production by aortic tissue, and this effect was
Fig. 6. Inhibition of xanthine oxidoreductase (XOR) with febuxostat blunts the endothelial dysfunction caused by chronic treatment with omeprazole, both in normotensive
and in hypertensive rats. (a) Endothelial cell-dependent vasorelaxation induced by acetylcholine (Ach) in aortic rings from normotensive rats chronically treated with
omeprazole (or vehicle) in the presence of the selective XOR inhibitor febuxostat (107 mol/L). The bars show the pD2 values ( log of the molar concentration of Ach that
produces 50% of the maximal effect) and the maximal responses to Ach. (b) Endothelial cell-dependent vasorelaxation induced by acetylcholine (Ach) in aortic rings from
2k1C hypertensive rats chronically treated with omeprazole (or vehicle) in the presence of the selective XOR inhibitor febuxostat (107 mol/L). The bars show the pD2 values
(log of the molar concentration of Ach that produces 50% of the maximal effect) and the maximal responses to Ach. Data are shown as mean7S.E.M. (n¼4–5/group).
*Po0.05 versus respective Vehicle group. #Po0.05 for OmeprazoleþFebuxostat group versus OmeprazoleþVehicle group.
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plicating XOR.
Given that increased vascular oxidative stress is a major factor
leading to endothelial dysfunction [33], and that XOR activation
may promote both alterations [34], it is reasonable to accept that
omeprazole increased ADMA levels which, in turn, promoted XOR-
mediated vascular redox imbalance and impaired endothelial-de-
pendent responses to acetylcholine. Although molecular me-
chanisms have not been investigated in the present study, it is
possible that NOS inhibition by ADMA may have increased XOR
activity and therefore explain our biochemical and functional
findings. This suggestion is supported by previous studies showing
that NOS deficiency stimulates XOR activity and depresses myo-
cardial function, an effect that is reversible by XOR inhibition [35],
exactly as we have shown in the present study using the selective
XOR inhibitor febuxostat. In addition to this mechanism, super-
oxide produced by increased XOR activity may react with en-
dogenous NO producing peroxynitrite [13,36], and thus impair NO
activity and cause endothelial dysfunction, as we have reported
here with omeprazole. This XOR-dependent mechanism agrees
with a previous study showing that increased vascular XOR ac-
tivity could play a critical role in endothelial dysfunction, which is
at least partially prevented by XOR inhibition [37].
Hypertensive patients may require the use of PPIs in a number
of clinical conditions. Because patients with hypertension or other
cardiovascular diseases may be more sensitive to the deleterious
effects of PPIs-induced increases in ADMA levels [38], we studied
the effects of omeprazole in 2K1C hypertensive rats. While this PPI
significantly impaired vascular redox biology and function, it did
not aggravate hypertension-induced endothelial dysfunction. It is
possible that this hypertension model is so severe that near
maximum vascular damage is produced. It should be noted that a
pilot study showed that lansoprazole treatment did not affect
endothelial function in healthy subjects and in patients [38].
However, this was a short-term study (four weeks of lansoprazole)
and the technique used to assess vascular function may offer sig-
nificant limitations [30]. Further studies are required to confirm
that omeprazole does not further deteriorate the vascular function
in a less severe hypertension model compared to ours, as well as in
patients.
Our results indicate that omeprazole increases vascular XOR
activity. Interestingly, our findings may explain the development
of acute gout in two patients, as previously reported [39]. The
authors suggested a causal relation between the use of omerpra-
zole and acute gout in two patients, without offering a possible
mechanism [39]. One of the patients developed a second episode
of gout after rechallenge with omeprazole [39]. Our results
showing increased XOR activity with omeprazole is consistent
with increased conversion of hypoxanthine to xanthine and xan-
thine to uric acid in patient taking omeprazole, thus increasing the
risk of acute gout. Maybe uric acid assessment should be re-
commended to patients taking omeprazole.
In summary, our results demonstrate that treatment with
omeprazole impairs the vascular function to the same extent as
renovascular hypertension. This deleterious effect of omeprazole is
probably mediated by increased ADMA concentrations leading to
enhanced vascular XOR activity and oxidative stress. Our findings
show an important mechanism involving impaired redox vascular
biology associated with omeprazole treatment, which may be
clinically relevant in patients taking other PPIs, particularly those
exposed to other factors increasing the cardiovascular risk.
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